ReviewOncogene2013
Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?
Review in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 87 citations in OpenAlex.
- When Do Tumours Develop? Neoplastic Processes Across Different Timescales: Age, Season and Round the Circadian Clock.Evolutionary applications · 2024Review
- A modelling framework for cancer ecology and evolution.Journal of the Royal Society, Interface · 2024Article
- A Poisson distribution-based general model of cancer rates and a cancer risk-dependent theory of aging.Aging · 2023Article
- Modeling of senescent cell dynamics predicts a late-life decrease in cancer incidence.Evolutionary applications · 2023Article
- Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs.The Journal of pathology · 2022Article
- Article
- Mutation or not, what directly establishes a neoplastic state, namely cellular immortality and autonomy, still remains unknown and should be prioritized in our research.Journal of Cancer · 2022Review
- Integrating genetic and nongenetic drivers of somatic evolution during carcinogenesis: The biplane model.Evolutionary applications · 2020Article
- Tumour Initiation: a Discussion on Evidence for a "Load-Trigger" Mechanism.Cell biochemistry and biophysics · 2019Review
- Aging and cancer: Is glucose a mediator between them?Oncotarget · 2019Article
- Tumorigenesis as the Paradigm of Quasi-neutral Molecular Evolution.Molecular biology and evolution · 2019Article
- Decoy fitness peaks, tumor suppression, and aging.Aging cell · 2019Article
- Article
- A matched cohort study of radio-chemotherapy versus radiotherapy alone in soft tissue sarcoma patients.La Radiologia medica · 2019Article
- Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker.American journal of ophthalmology · 2019Article
- Genetic diversity, inbreeding and cancer.Proceedings. Biological sciences · 2018Review
- Cell death-based treatment of childhood cancer.Cell death & disease · 2018Review
- Article
- Connecting Cancer to Its Causes Requires Incorporation of Effects on Tissue Microenvironments.Cancer research · 2017Article
- Cancer and intercellular cooperation.Royal Society open science · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
A widely accepted paradigm in cancer research holds that the development of cancers is rate limited by the occurrence of oncogenic mutations. In particular, the exponential rise in the incidence of most cancers with age is thought to reflect the time required for cells to accumulate the multiple oncogenic mutations needed to confer the cancer phenotype. Here I will argue against the axiom that the occurrence of oncogenic mutations limits cancer incidence with age, based on several observations, including that the rate of mutation accumulation is maximal during ontogeny, oncogenic mutations are frequently detected in normal tissues, the evolution of complex multicellularity was not accompanied by reductions in mutation rates, and that many oncogenic mutations have been shown to impair stem cell activity. Moreover, although evidence that has been used to support the current paradigm includes increased cancer incidence in individuals with inherited DNA repair deficiencies or exposed to mutagens, the pleotropic effects of these contexts could enhance tumorigenesis at multiple levels. I will further argue that age-dependent alteration of selection for oncogenic mutations provides a more plausible explanation for increased cancer incidence in the elderly. Although oncogenic mutations are clearly required for cancer evolution, together these observations counter the common view that age dependence of cancers is largely explained by the time required to accumulate sufficient oncogenic mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.